Japan· JP-1179033F2027
ミアンセリン塩酸塩
A mianserin product containing ミアンセリン塩酸塩, registered in Japan by オルガノン, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Mianserin is registered in 15 of 19 countries.
Countries holding a registration under ATC N06AX03 (mianserin), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 9 of them publish a price we can compare per daily dose
Mianserin · ATC N06AX03
15 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of mianserin costs, country by country.
Normalised to the WHO defined daily dose (60 mg), the median price runs from $0.32 in France to $1.15 in Switzerland — a ×3.6 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mianserin · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.15
- IT Italy$0.68
- FR France$0.32
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ミアンセリン塩酸塩
- Manufacturer
- オルガノン
- Country
- Japan (JP)
- ATC code
- N06AX03
- ATC class
- Mianserin
- Defined daily dose
- 60 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
19 interactions on record for mianserin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mianserin · interactions on record
19 records
19 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under N06AX03
Mianserin, as other registers publish it.
- PolandDeprexoletAdamed Pharma S.A.
- PolandDeprexoletAdamed Pharma S.A.
- PolandDeprexoletAdamed Pharma S.A.
- ItalyLANTANON*30 cpr rivestite 30 mgORGANON ITALIA Srl
- PolandLerivonOrganon Polska Sp. z o.o.
- PolandLerivonOrganon Polska Sp. z o.o.
- CzechiaLERIVONMerck Sharp & Dohme B.V., Haarlem
- CzechiaLERIVONN.V. Organon, Oss
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c9d55589-16d8-43b0-9eb8-3c2de007cde7 GET /v1/drugs/c9d55589-16d8-43b0-9eb8-3c2de007cde7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "３０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1179033F2027",
"category": "内用薬",
"price_yen": 21.3,
"generic_name": "ミアンセリン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "1179",
"transitional_expiry": null
}See everything about mianserin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.